Evidence map›Paper›PMID 37020153›Full record

Trial reportQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2023

Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03.

Thomas M Atkinson, Shelly Lensing, Jeannette Y Lee, Di Chang, Soo Young Kim, Yuelin Li, Kathleen A Lynch, Andrew Webb, Susan M Holland, Erica I Lubetkin and 25 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Impact of anal precancer screening on patient-reported outcomes among men-who-have-sex-with-men living with HIV: a scoping review.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 1 country.

Thomas M AtkinsonDepartment of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 633 Third Ave, New York, NY, 10017, USA. atkinsot@mskcc.org.ORCID http://orcid.org/0000-0002-4965-3913
Shelly LensingUniversity of Arkansas for Medical Sciences, Little Rock, AR, USA.
Jeannette Y LeeUniversity of Arkansas for Medical Sciences, Little Rock, AR, USA.
Di ChangUniversity of Arkansas for Medical Sciences, Little Rock, AR, USA.
Soo Young KimDepartment of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 633 Third Ave, New York, NY, 10017, USA.
Yuelin LiDepartment of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 633 Third Ave, New York, NY, 10017, USA.
Kathleen A LynchDepartment of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 633 Third Ave, New York, NY, 10017, USA.
Andrew WebbDepartment of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 633 Third Ave, New York, NY, 10017, USA.
Susan M HollandDepartment of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 633 Third Ave, New York, NY, 10017, USA.
Erica I LubetkinCUNY School of Medicine, New York, NY, USA.
Stephen GoldstoneLaser Surgery Care, New York, NY, USA.
Mark H EinsteinRutgers-New Jersey Medical School, Newark, NJ, USA.
Elizabeth A StierBoston Medical Center, Boston, MA, USA.
Dorothy J WileyUniversity of California, Los Angeles School of Nursing, Los Angeles, CA, USA.
Ronald MitsuyasuUCLA Center for Clinical AIDS Research and Education, Los Angeles, CA, USA.
Isabella Rosa-CunhaJackson Memorial Hospital, Miami, FL, USA.
David M AboulafiaVirginia Mason Medical Center, Seattle, WA, USA.
Shireesha DhanireddyHarborview Medical Center, Seattle, WA, USA.
Jeffrey T SchoutenVirginia Mason Medical Center, Seattle, WA, USA.
Rebecca LevineMontefiore Medical Center, New York, NY, USA.
Edward GardnerPublic Health Institute at Denver Health, Denver, CO, USA.
Jeffrey LoganPublic Health Institute at Denver Health, Denver, CO, USA.
Hillary DunleavyUniversity of Colorado Hospital, Aurora, CO, USA.
Luis F BarrosoAtrium Health Wake Forest Baptist, Winston-Salem, NC, USA.
Gary BucherAnal Dysplasia Clinic MidWest, Chicago, IL, USA.
Jessica KormanMetropolitan Gastroenterology Group, Washington, DC, USA.
Benjamin StearnDupont Circle Physicians Group PC, Washington, DC, USA.
Timothy J WilkinWeill Cornell Medicine, New York, NY, USA.
Grant EllsworthWeill Cornell Medicine, New York, NY, USA.
Julia C PuglieseANCHOR Data Management Center of The Emmes Company, LLC, Rockville, MD, USA.
Abigail AronsANCHOR Data Management Center of The Emmes Company, LLC, Rockville, MD, USA.
Jack E BurkhalterDepartment of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 633 Third Ave, New York, NY, 10017, USA.
David CellaNorthwestern University Feinberg School of Medicine, Chicago, IL, USA.
J Michael Berry-LawhornUniversity of California, San Francisco, CA, USA.
Joel M PalefskyUniversity of California, San Francisco, CA, USA.
Memorial Sloan Kettering Cancer Center · USUniversity of Arkansas for Medical Sciences · USCornell University · USDenver Health Medical Center · USEmmes (United States) · USUniversity of California, San Francisco · USVirginia Mason Medical Center · USAPLA Health · USAtrium Health Wake Forest Baptist · USBoston University · USCUNY School of Law · USDermatology Surgery & Laser Center · USHarborview Medical Center · USJackson Memorial Hospital · USMontefiore Medical Center · USNorthwestern University · USRutgers, The State University of New Jersey · USUniversity of California, Los Angeles · USUniversity of Colorado Hospital · USUniversity Physicians · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Consortium for Advancing Management and Prevention of Cancer in People with HIVUM1CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Joseph A. Sparano · 2015 to 2026
$253.7M
University of Southern CaliforniaU01CA121947 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI STIER, ELIZABETH A. · 2006 to 2014
$54.7M
Training and Career Development and Education CoreU54CA137788 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Daniel Alan Heller · 2008 to 2026
$28.1M
NCI NIH HHS P30 CA008748NCI NIH HHS U01 CA121947NCI NIH HHS U54 CA137788NCI NIH HHS UM1 CA121947NIH HHS 2 UM1 CA121947-09NIH HHS 3U54CA137788-08S1NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeTo determine whether treatment of anal high-grade squamous intraepithelial lesions (HSIL), vs active monitoring, is effective in reducing incidence of anal cancer in persons living with HIV, the US National Cancer Institute funded the Phase III ANal Cancer/HSIL Outcomes Research (ANCHOR) clinical trial. As no established patient-reported outcomes (PRO) tool exists for persons with anal HSIL, we sought to estimate the construct validity and responsiveness of the ANCHOR Health-Related Symptom Index (A-HRSI).

methodsThe construct validity phase enrolled ANCHOR participants who were within two weeks of randomization to complete A-HRSI and legacy PRO questionnaires at a single time point. The responsiveness phase enrolled a separate cohort of ANCHOR participants who were not yet randomized to complete A-HRSI at three time points: prior to randomization (T1), 14-70 (T2), and 71-112 (T3) days following randomization.

resultsConfirmatory factor analysis techniques established a three-factor model (i.e., physical symptoms, impact on physical functioning, impact on psychological functioning), with moderate evidence of convergent validity and strong evidence of discriminant validity in the construct validity phase (n = 303). We observed a significant moderate effect for changes in A-HRSI impact on physical functioning (standardized response mean = 0.52) and psychological symptoms (standardized response mean = 0.60) from T2 (n = 86) to T3 (n = 92), providing evidence of responsiveness.

conclusionA-HRSI is a brief PRO index that captures health-related symptoms and impacts related to anal HSIL. This instrument may have broad applicability in other contexts assessing individuals with anal HSIL, which may ultimately help improve clinical care and assist providers and patients with medical decision-making.

Indexed as

Anus NeoplasmsHIV InfectionsSquamous Intraepithelial LesionsAnal CanalHumansQuality of LifeSurveys and QuestionnairesAnus neoplasmsHIVNeoplasmsPatient reported outcome measuresPsychometricsQuality of life

Identifiers

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.